

Dae-Seog Heo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/105929/dae-seog-heo-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

318
papers

12,754
citations

56
h-index

100
g-index

330
ext. papers

14,311
ext. citations

4.1
avg, IF

5.94
L-index

#	Paper	IF	Citations
318	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology, The</i> , 2012 , 13, 528-38	21.7	777
317	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2493-501	2.2	681
316	Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. <i>Clinical Cancer Research</i> , 2004 , 10, 3708-16	12.9	644
315	Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. <i>Journal of Immunology</i> , 2004 , 172, 7335-40	5.3	417
314	A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. <i>Cancer</i> , 1993 , 71, 3813-8	6.4	323
313	Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2965-71	2.2	230
312	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3065-3074	2.2	229
311	Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. <i>Clinical Cancer Research</i> , 2006 , 12, 2538-44	12.9	215
310	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3337-44	2.2	214
309	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2016 , 22, 2261-70	12.9	164
308	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , 2011 , 13, R22	8.3	158
307	MicroRNA-146a downregulates NFB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. <i>Clinical Cancer Research</i> , 2011 , 17, 4761-71	12.9	153
306	Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5233-9	2.2	150
305	The attitudes of cancer patients and their families toward the disclosure of terminal illness. <i>Journal of Clinical Oncology</i> , 2004 , 22, 307-14	2.2	147
304	Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , 2005 , 106, 3785-90	2.2	145
303	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. <i>International Journal of Cancer</i> , 2005 , 113, 109-15	7.5	139
302	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1474-80	8.9	131

301	Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. <i>Annals of Oncology</i> , 2008 , 19, 1477-1484	10.3	119
300	Experiences and attitudes of patients with terminal cancer and their family caregivers toward the disclosure of terminal illness. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1950-7	2.2	118
299	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. <i>Cancer</i> , 2013 , 119, 1195-202	6.4	117
298	Palliative chemotherapy for pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2007 , 58, 112-5	5.9	111
297	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. <i>BMC Cancer</i> , 2007 , 7, 203	4.8	111
296	Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. <i>Oncology</i> , 2004 , 66, 439-44	3.6	109
295	Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1430-7	27.4	107
294	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , 2009 , 65, 80-4	5.9	105
293	Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2012 , 77, 288-92	5.9	102
292	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. <i>Histopathology</i> , 2016 , 68, 1079-89	7.3	102
291	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 15901-14	3.3	101
290	Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 54, 414-9	4	95
289	Docetaxel 75 mg/m ² is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2002 , 32, 248-54	2.8	92
288	Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. <i>Cancer Immunology Research</i> , 2016 , 4, 215-24	12.5	90
287	Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. <i>Japanese Journal of Cancer Research</i> , 2002 , 93, 471-7		90
286	Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2379-87	12.9	89
285	Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1069-74	8.9	88
284	Aggressiveness of cancer-care near the end-of-life in Korea. <i>Japanese Journal of Clinical Oncology</i> , 2008 , 38, 381-6	2.8	85

283	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016 , 17, 263-270.e2	4.9	82
282	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 459-470	7.4	82
281	GCT-02. THE LONG-TERM OUTCOMES AND SEQUELAE ANALYSIS OF INTRACRANIAL GERMINOMA FROM 187 PATIENTS IN THE SINGLE INSTITUTE: NECESSITY FOR THE ADAPTATION OF RADIOTHERAPY DOSE AND VOLUME. <i>Neuro-Oncology</i> , 2020 , 22, iii328-iii329	1	78
280	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 15035-49	3.3	77
279	Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. <i>Lung Cancer</i> , 2008 , 61, 30-4	5.9	76
278	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2015 , 47, 607-15	5.2	76
277	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017 , 8, 1050	17.4	75
276	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008 , 60, 401-7	5.9	72
275	Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. <i>Tumor Biology</i> , 2008 , 29, 28-34	2.9	72
274	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. <i>Lung Cancer</i> , 2012 , 77, 460-3	5.9	71
273	Prognostic factors of Krukenberg's tumor. <i>Gynecologic Oncology</i> , 2001 , 82, 105-9	4.9	68
272	Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. <i>Cancer</i> , 2004 , 100, 1961-6	6.4	67
271	Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma. <i>Acta Oncologica</i> , 2003 , 42, 779-83	3.2	66
270	CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. <i>Tumor Biology</i> , 2012 , 33, 121-9	2.9	65
269	Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. <i>Japanese Journal of Clinical Oncology</i> , 2003 , 33, 608-12	2.8	64
268	The role of PET/CT in detection of gastric cancer recurrence. <i>BMC Cancer</i> , 2009 , 9, 73	4.8	62
267	Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. <i>Cancer</i> , 2004 , 101, 2257-60	6.4	61
266	Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2474-80	2.2	60

265	The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. <i>International Journal of Cancer</i> , 2003 , 107, 729-38	7.5	60
264	Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. <i>Lung Cancer</i> , 2012 , 77, 572-7	5.9	58
263	Factors influencing preferences for place of terminal care and of death among cancer patients and their families in Korea. <i>Supportive Care in Cancer</i> , 2005 , 13, 565-72	3.9	57
262	Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. <i>BMC Cancer</i> , 2008 , 8, 148	4.8	56
261	Impact of caregivers' unmet needs for supportive care on quality of terminal cancer care delivered and caregiver's workforce performance. <i>Supportive Care in Cancer</i> , 2010 , 18, 699-706	3.9	55
260	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. <i>BMC Cancer</i> , 2007 , 7, 63	4.8	55
259	Chemotherapy use and associated factors among cancer patients near the end of life. <i>Oncology</i> , 2007 , 72, 164-71	3.6	55
258	CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience. <i>Supportive Care in Cancer</i> , 2006 , 14, 103-8	3.9	55
257	Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies. <i>Cancer Science</i> , 2009 , 100, 2242-8	6.9	54
256	Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 905-12	8.9	53
255	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 469, 581-590	5.1	53
254	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 303-13	4.8	52
253	Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. <i>Cancer</i> , 2003 , 98, 2651-6	6.4	52
252	First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1274-82	1.9	51
251	Attitudes of cancer patients, family caregivers, oncologists and members of the general public toward critical interventions at the end of life of terminally ill patients. <i>Cmaj</i> , 2011 , 183, E673-9	3.5	50
250	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 313-9	1.9	49
249	Multicenter study of pain and its management in patients with advanced cancer in Korea. <i>Journal of Pain and Symptom Management</i> , 2003 , 25, 430-7	4.8	49
248	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017 , 8, 97920-97927	3.3	49

247	Patient Autonomy and Advance Directives in Korea. <i>Journal of the Korean Medical Association</i> , 2009 , 52, 865	0.5	46
246	Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 1999 , 60, 205-14	7.1	46
245	Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines. <i>Oncogene</i> , 2005 , 24, 6689-98	9.2	45
244	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. <i>Supportive Care in Cancer</i> , 2013 , 21, 1437-44	3.9	43
243	Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, e147-50	2.2	43
242	Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. <i>Laryngoscope</i> , 2008 , 118, 663-70	3.6	42
241	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. <i>Cancer</i> , 2012 , 118, 3579-86	6.4	41
240	Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 320-5	8.9	41
239	Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. <i>BMC Cancer</i> , 2008 , 8, 374	4.8	41
238	Epstein-Barr virus-associated peripheral T-cell lymphoma in adults with hydroa vacciniforme-like lesions. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 242-7	1.8	41
237	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. <i>Cancer Research and Treatment</i> , 2015 , 47, 555-63	5.2	40
236	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. <i>BMC Cancer</i> , 2019 , 19, 19	4.8	40
235	MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2015 , 90, 381-7	5.9	39
234	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 153-60	4.4	39
233	A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002 , 25, 238-43	2.7	39
232	Upfront chemotherapy and involved-field radiotherapy results in more relapses than extended radiotherapy for intracranial germinomas: modification in radiotherapy volume might be needed. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 667-71	4	38
231	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>American Journal of Pathology</i> , 2017 , 187, 980-986	5.8	37
230	Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. <i>Annals of Hematology</i> , 2015 , 94, 575-81	3	36

229	First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors. <i>Cancer Science</i> , 2010 , 101, 1199-203	6.9	36
228	Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1778-86	1.9	35
227	Advanced hypopharyngeal carcinoma treatment results according to treatment modalities. <i>Head and Neck</i> , 2001 , 23, 713-7	4.2	35
226	Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. <i>BMC Cancer</i> , 2010 , 10, 448	4.8	34
225	High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. <i>Clinical Cancer Research</i> , 2006 , 12, 4232-6	12.9	34
224	EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care units. <i>Supportive Care in Cancer</i> , 2006 , 14, 329-33	3.9	34
223	Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. <i>European Journal of Surgical Oncology</i> , 2001 , 27, 464-71	3.6	34
222	Clinical Implications of VEGF, TGF- β , and IL-1 β in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013 , 45, 325-33	5.2	34
221	Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2032-8	1.9	33
220	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. <i>Clinical Lung Cancer</i> , 2019 , 20, 331-338.e4	4.9	32
219	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. <i>ESMO Open</i> , 2018 , 3, e000332	6	32
218	Use of a decision aid to help caregivers discuss terminal disease status with a family member with cancer: a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4811-9	2.2	32
217	Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. <i>Cancer Research</i> , 2004 , 64, 3230-5	10.1	32
216	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. <i>BMC Cancer</i> , 2016 , 16, 363	4.8	32
215	Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. <i>Neuropathology</i> , 2009 , 29, 443-9	2	31
214	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2006 , 54, 201-7	5.9	31
213	Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. <i>Supportive Care in Cancer</i> , 2013 , 21, 183-90	3.9	30
212	Patient-reported assessment of quality care at end of life: development and validation of Quality Care Questionnaire-End of Life (QCQ-EOL). <i>European Journal of Cancer</i> , 2006 , 42, 2310-7	7.5	30

211	Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. <i>Cancer</i> , 2000 , 89, 2521-6	6.4	30
210	PPAR α ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 406, 389-95	3.4	29
209	Comparative analysis of NK/T-cell lymphoma and peripheral T-cell lymphoma in Korea: Clinicopathological correlations and analysis of EBV strain type and 30-bp deletion variant LMP1. <i>Pathology International</i> , 2003 , 53, 735-43	1.8	29
208	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. <i>PLoS ONE</i> , 2018 , 13, e0189766	3.7	28
207	Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation. <i>European Journal of Immunology</i> , 2015 , 45, 2335-42	6.1	27
206	A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. <i>Lung Cancer</i> , 2011 , 71, 65-9	5.9	27
205	Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , 2009 , 31, 1121-8	4.2	27
204	Clinical dissection of multicentric Castleman disease. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1517-22	1.9	27
203	Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. <i>Cancer Research and Treatment</i> , 2019 , 51, 951-962	5.2	27
202	The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancer Research and Treatment</i> , 2016 , 48, 907-16	5.2	27
201	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. <i>Scientific Reports</i> , 2019 , 9, 7680	4.9	26
200	Integration of palliative and supportive cancer care in Asia. <i>Lancet Oncology</i> , 2012 , 13, 445-6	21.7	26
199	The life-sustaining treatments among cancer patients at end of life and the caregiver's experience and perspectives. <i>Supportive Care in Cancer</i> , 2010 , 18, 189-96	3.9	26
198	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. <i>Korean Journal of Internal Medicine</i> , 2016 , 31, 570-8	2.5	26
197	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. <i>Anticancer Research</i> , 2015 , 35, 175-82	2.3	26
196	Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. <i>BMC Cancer</i> , 2016 , 16, 116	4.8	25
195	The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. <i>Cellular Oncology (Dordrecht)</i> , 2012 , 35, 1-8	7.2	25
194	Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. <i>International Journal of Oncology</i> , 2012 , 41, 76-82	4.4	25

193	Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 595-602	4.8	25
192	The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 336, 516-23	4.7	25
191	Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006 , 36, 344-50	2.8	25
190	Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2003 , 39, 99-101	5.9	25
189	Risk factors for ovarian metastasis following curative resection of gastric adenocarcinoma 1999 , 85, 1490-1499	2.5	
188	Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. <i>Leukemia and Lymphoma</i> , 2017 , 58, 53-63	1.9	24
187	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia</i> , 2020 , 34, 2184-2197	10.7	24
186	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. <i>BMC Cancer</i> , 2016 , 16, 170	4.8	24
185	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011 , 137, 1301-8	4.9	24
184	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2009 , 65, 204-7	5.9	24
183	Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer. <i>Cancer Investigation</i> , 2008 , 26, 152-8	2.1	24
182	Targeted therapy of DNA tumor virus-associated cancers using virus-activated transcription factors. <i>Molecular Therapy</i> , 2006 , 13, 899-909	11.7	24
181	Validation study of the Korean version of the McGill Quality of Life Questionnaire. <i>Palliative Medicine</i> , 2007 , 21, 441-7	5.5	24
180	Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. <i>Cancer Research and Treatment</i> , 2017 , 49, 416-422	5.2	24
179	Effect of advanced cancer patients' awareness of disease status on treatment decisional conflicts and satisfaction during palliative chemotherapy: a Korean prospective cohort study. <i>Supportive Care in Cancer</i> , 2012 , 20, 1309-16	3.9	23
178	Characteristics and issues of guideline to withdrawal of a life-sustaining therapy. <i>Journal of the Korean Medical Association</i> , 2011 , 54, 747	0.5	23
177	Chylothorax in Gorham's disease. <i>Journal of Korean Medical Science</i> , 2002 , 17, 826-9	4.7	23
176	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Korean Journal of Internal Medicine</i> , 2016 , 31, 1140-1149	2.5	23

175	Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 670-5	5.2	23
174	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018 , 9, 736-744	3.2	22
173	Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer. <i>Journal of Korean Medical Science</i> , 2007 , 22 Suppl, S115-21	4.7	22
172	Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. <i>Cancer</i> , 1999 , 86, 1109-15	6.4	21
171	The Association between End-of-Life Care and the Time Interval between Provision of a Do-Not-Resuscitate Consent and Death in Cancer Patients in Korea. <i>Cancer Research and Treatment</i> , 2017 , 49, 502-508	5.2	21
170	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. <i>Oncologist</i> , 2019 , 24, e740-e748	5.7	21
169	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2019 , 24, 20-e29	5.7	21
168	Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines. <i>Head and Neck</i> , 2010 , 32, 1534-43 ^{4,2}		20
167	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. <i>Lung Cancer</i> , 2019 , 136, 122-128	5.9	19
166	EGFR mutations as a predictive marker of cytotoxic chemotherapy. <i>Lung Cancer</i> , 2012 , 77, 433-7	5.9	19
165	Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. <i>Japanese Journal of Clinical Oncology</i> , 2010 , 40, 542-8	2.8	19
164	Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2004 , 34, 400-4	2.8	19
163	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2016 , 22, 8389-8397	5.6	19
162	Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 45, 901-5	4	18
161	Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy. <i>Radiation Oncology Journal</i> , 2015 , 33, 98-108	2.5	18
160	Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives. <i>Cancer Research and Treatment</i> , 2018 , 50, 614-623	5.2	18
159	Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 119-127	5.2	18
158	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. <i>Theranostics</i> , 2020 , 10, 10838-10848	12.1	18

157	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. <i>Oncologist</i> , 2015 , 20, 1119-20	5.7	17
156	The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015 , 194, 1112-9	2.5	17
155	Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. <i>BMC Cancer</i> , 2011 , 11, 435	4.8	17
154	Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. <i>Lung Cancer</i> , 2008 , 62, 381-4	5.9	17
153	Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005 , 35, 720-6	2.8	17
152	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancer Research and Treatment</i> , 2014 , 46, 323-30	5.2	17
151	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. <i>Cancer Research and Treatment</i> , 2015 , 47, 630-7	5.2	17
150	Complementary and alternative medicine use among cancer patients at the end of life: Korean national study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012 , 13, 1419-24	1.7	17
149	Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial. <i>Thoracic Cancer</i> , 2020 , 11, 62-71	3.2	17
148	Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 91-8	4	16
147	Health economics of a palliative care unit for terminal cancer patients: a retrospective cohort study. <i>Supportive Care in Cancer</i> , 2012 , 20, 29-37	3.9	16
146	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2012 , 20, 395-403	3.9	16
145	Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. <i>BMC Cancer</i> , 2009 , 9, 450	4.8	16
144	Inhibitory effect of p27KIP1 gene transfer on head and neck squamous cell carcinoma cell lines. <i>Head and Neck</i> , 2003 , 25, 44-9	4.2	16
143	Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. <i>Journal of Korean Medical Science</i> , 2005 , 20, 806-10	4.7	16
142	Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 2000 , 111, 216-22	4.5	16
141	Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2016 , 7, 161-6	3.2	16
140	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1556-1566	8.9	15

139	Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. <i>Cancer Science</i> , 2012 , 103, 155-60	6.9	15
138	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 520-528	8.9	15
137	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score. <i>Lung Cancer</i> , 2014 , 86, 363-8	5.9	15
136	Discrepancies in performance status scores as determined by cancer patients and oncologists: are they influenced by depression?. <i>General Hospital Psychiatry</i> , 2007 , 29, 555-61	5.6	15
135	Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>Clinical Lung Cancer</i> , 2016 , 17, 245-252.e1	4.9	15
134	Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. <i>Journal of Korean Medical Science</i> , 2014 , 29, 1094-101	4.7	14
133	A possible mechanism of impaired NK cytotoxicity in cancer patients: Down-regulation of DAP10 by TGF- β . <i>Tumori</i> , 2011 , 97, 350-357	1.7	14
132	Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. <i>Annals of Hematology</i> , 2009 , 88, 829-38	3	14
131	Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line. <i>Oncology Reports</i> , 2010 , 23, 1139-43	3.5	14
130	Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005 , 35, 380-5	2.8	14
129	Enhancement of adenoviral transduction with polycationic liposomes in vivo		14
128	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 873-83	4.9	13
127	Terminal cancer patients' and their primary caregivers' attitudes toward hospice/palliative care and their effects on actual utilization: A prospective cohort study. <i>Palliative Medicine</i> , 2014 , 28, 976-985	5.5	13
126	A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group. <i>Oncologist</i> , 2014 , 19, 1129-30	5.7	13
125	Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. <i>Supportive Care in Cancer</i> , 2007 , 15, 631-636	3.9	13
124	A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma. <i>Cancer</i> , 2004 , 101, 2516-22	6.4	13
123	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2016 , 16, 425-33	3.8	13
122	Presence of membrane-bound TGF-beta1 and its regulation by IL-2-activated immune cell-derived IFN-gamma in head and neck squamous cell carcinoma cell lines. <i>Journal of Immunology</i> , 2009 , 182, 6114-20	5.3	12

121	Synergistic anti-tumor effects with co-expression of GM-CSF and IFN-gamma in murine tumors. <i>International Journal of Cancer</i> , 1998 , 77, 907-12	7.5	12
120	Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines. <i>International Journal of Molecular Medicine</i> , 2009 , 23, 805-10	4.4	12
119	A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. <i>Cancer</i> , 2001 , 91, 1549-56	6.4	12
118	Progress and limitations in cancer gene therapy. <i>Genetics in Medicine</i> , 2002 , 4, 52S-55S	8.1	12
117	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2017 , 32, 514-522	2.5	12
116	Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. <i>Cancer Research and Treatment</i> , 2016 , 48, 88-97	5.2	12
115	Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients. <i>Cancer Research and Treatment</i> , 2020 , 52, 917-924	5.2	12
114	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). <i>Lung Cancer</i> , 2016 , 93, 1-8	5.9	11
113	Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1567-74	4.9	11
112	Depression, suicide, and Korean society. <i>Journal of the Korean Medical Association</i> , 2011 , 54, 358	0.5	11
111	Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009 , 65, 242-6	5.9	11
110	Herpes simplex virus thymidine kinase and granulocyte macrophage colony-stimulating factor combination gene therapy in a murine CT26 cell colon cancer model. <i>Cancer Gene Therapy</i> , 2004 , 11, 570-574	5.4	11
109	Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2-microglobulin gene in patients with cancer. <i>Human Gene Therapy</i> , 1998 , 9, 2031-8	4.8	11
108	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9013-9013	2.2	11
107	Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases. <i>Oral Oncology</i> , 2019 , 89, 84-94	4.4	11
106	A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2019 , 24, 751-e231	5.7	10
105	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, e442-e451	4.9	10
104	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017 , 49, 1033-1043	5.2	10

103	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. <i>Head and Neck</i> , 2016 , 38, 277-84	4.2	10
102	Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2012 , 42, 948-54	2.8	10
101	Neoadjuvant chemotherapy and radiotherapy for the treatment of advanced hypopharyngeal carcinoma. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 1998 , 19, 40-4	2.8	10
100	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?. <i>Korean Journal of Internal Medicine</i> , 2019 , 34, 1313-1323	2.5	10
99	Consensus guidelines for the definition of the end stage of disease and last days of life and criteria for medical judgment. <i>Journal of the Korean Medical Association</i> , 2018 , 61, 509	0.5	10
98	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. <i>Cytotherapy</i> , 2019 , 21, 603-611	4.8	9
97	The Understanding of Terminal Cancer and Its Relationship with Attitudes toward End-of-Life Care Issues. <i>Medical Decision Making</i> , 2014 , 34, 720-30	2.5	9
96	Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma. <i>Cancer Science</i> , 2010 , 101, 482-7	6.9	9
95	End-of-life Decision in Korea. <i>Journal of the Korean Medical Association</i> , 2008 , 51, 524	0.5	9
94	Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. <i>Lung Cancer</i> , 2006 , 52, 75-81	5.9	9
93	Tracheal glomangiosarcoma with multiple skin metastasis. <i>Journal of Dermatology</i> , 2004 , 31, 776-8	1.6	9
92	The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer. <i>Cancer Research and Treatment</i> , 2018 , 50, 720-728	5.2	9
91	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Research and Treatment</i> , 2019 , 51, 1231-1240	5.2	9
90	CD21-independent Epstein-Barr virus entry into NK cells. <i>Cellular Immunology</i> , 2018 , 327, 21-25	4.4	8
89	Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. <i>Cancer Research and Treatment</i> , 2016 , 48, 304-11	5.2	8
88	Changes in health-related quality of life and quality of care among terminally ill cancer patients and survival prediction: Multicenter prospective cohort study. <i>Palliative and Supportive Care</i> , 2015 , 13, 1103-1115	2.5	8
87	Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. <i>Cancer Science</i> , 2011 , 102, 1972-6	6.9	8
86	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2015 , 30, 891-8	2.5	8

85	Severe late dysphagia after multimodal treatment of stage III/IV laryngeal and hypopharyngeal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 185-192	2.8	8
84	An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1956-60	1.9	7
83	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. <i>PLoS ONE</i> , 2015 , 10, e0133371	3.7	7
82	EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 548-54	2.8	7
81	Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1502-10	4.6	7
80	Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines. <i>Head and Neck</i> , 2004 , 26, 706-15	4.2	7
79	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. <i>Scientific Reports</i> , 2021 , 11, 19712	4.9	7
78	Clinical Application of Next-Generation Sequencing-Based Panel to Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 937-944	6.1	7
77	Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 940-3	1.9	6
76	The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines. <i>Anti-Cancer Drugs</i> , 2011 , 22, 416-23	2.4	6
75	Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II). <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 41, 109-16	3.5	6
74	Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer. <i>Head and Neck</i> , 2008 , 30, 346-50	4.2	6
73	A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8575-8575	2.2	6
72	Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2624-2632	1.9	5
71	Efficacy of cyclophosphamide, doxorubicin, and cisplatin for adenoid cystic carcinoma, and their relationship with the pre-chemotherapy tumor growth rate. <i>Chinese Clinical Oncology</i> , 2020 , 9, 15	2.3	5
70	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2018 , 59, 202-210 ³		5
69	The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: a retrospective cohort study. <i>Lung Cancer</i> , 2014 , 85, 320-5	5.9	5
68	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 68, 427-32	5.9	5

67	Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center. <i>Hematology</i> , 2011 , 16, 73-9	2.2	5
66	Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 245-52	2.8	5
65	Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome. <i>Journal of Korean Medical Science</i> , 2006 , 21, 633-8	4.7	5
64	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07. <i>Thoracic Cancer</i> , 2020 , 11, 3482-3489	3.2	5
63	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019 , 4, e000575	6	5
62	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 2117-2123	3.2	4
61	A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC. <i>Tumor Biology</i> , 2010 , 31, 659-66	2.9	4
60	Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005 , 35, 6-12	2.8	4
59	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study. <i>Blood</i> , 2018 , 132, 1617-1617	2.2	4
58	Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Cancer Research and Treatment</i> , 2018 , 50, 670-680	5.2	4
57	Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma. <i>Korean Journal of Internal Medicine</i> , 2021 , 36, 175-181	2.5	4
56	VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. <i>Diagnostic Molecular Pathology</i> , 2011 , 20, 143-7		3
55	Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment. <i>Acta Oto-Laryngologica</i> , 2007 , 121-7	1.6	3
54	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CChelN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7500-7500	2.2	3
53	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. <i>Korean Journal of Internal Medicine</i> , 2019 , 34, 885-893	2.5	3
52	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2019 , 34, 1116-1124	2.5	3
51	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 182-8	5.2	3
50	Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. <i>Cancer Research and Treatment</i> , 2017 , 49, 129-140	5.2	3

49	The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. <i>Cancer Research and Treatment</i> , 2019 , 51, 169-177	5.2	3
48	Depression and suicide in Korean society. <i>Journal of the Korean Medical Association</i> , 2011 , 54, 356	0.5	3
47	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. <i>Cancer Letters</i> , 2020 , 495, 135-144	9.9	3
46	Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 619-630	3.2	3
45	Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis. <i>Chemotherapy</i> , 2009 , 55, 145-54	3.2	2
44	Nonsurgical Treatment of an Incompletely Excised Primary Adenocarcinoma of Nonpigmented Ciliary Epithelium. <i>Tumori</i> , 2007 , 93, 514-517	1.7	2
43	A randomized, multicenter, open phase II study of cetuximab with docetaxel, cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6069-6069	2.2	2
42	The Necessity for End-of-Life Care Education: A Preliminary Analysis with Interns at Two University Hospitals. <i>The Korean Journal of Hospice and Palliative Care</i> , 2017 , 20, 111-121	0.5	2
41	Clinicopathologic features of surgically resected primary gastric lymphoma. <i>World Journal of Gastroenterology</i> , 2004 , 10, 1103-9	5.6	2
40	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1605-1617	7.4	2
39	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1755-1769	7.4	2
38	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021 , 10, 699-711	4.4	2
37	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1859-1871	8.9	2
36	Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement. <i>The Korean Journal of Hospice and Palliative Care</i> , 2022 , 25, 1-11	0.5	2
35	The fantasy of a new healthcare policy in Korea. <i>Journal of the Korean Medical Association</i> , 2017 , 60, 936	0.5	1
34	How to build successful hospice-palliative care systems in Korea. <i>Journal of the Korean Medical Association</i> , 2017 , 60, 352	0.5	1
33	Personalized cancer medicine: present status and future perspectives. <i>Journal of the Korean Medical Association</i> , 2015 , 58, 1021	0.5	1
32	Clinical significance of downstaging in patients with limited-disease small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2014 , 15, e1-6	4.9	1

31	Neoadjuvant Chemotherapy Followed by Radiotherapy in Epidermoid Carcinoma of Anus. <i>Tumori</i> , 2004 , 90, 299-302	1.7	1
30	A Spindle Cell Tumor of Unknown Origin and Diffuse Bone Marrow Involvement in a Patient with Hypercalcemia. <i>Tumori</i> , 1999 , 85, 526-529	1.7	1
29	International comparison on the factors influencing reimbursement of expensive cancer drugs.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6614-6614	2.2	1
28	Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2021 , 36, 975-984	2.5	1
27	The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives 2013 , 21, 1437		1
26	Justifying the Information on Hospice Care that octors should provide to Terminally Ill Patients. <i>Korean Journal of Medical Ethics</i> , 2010 , 13, 107-122	0	1
25	A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. <i>Haematologica</i> , 2021 , 106, 2277-2280	6.6	1
24	Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study. <i>Cancer Research and Treatment</i> , 2021 , 53, 584-592	5.2	1
23	The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2016 , 34, 145-150	2.2	1
22	Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae. <i>Cancer Research and Treatment</i> , 2021 , 53, 983-990	5.2	1
21	Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2021 , 11, 2514	4.9	1
20	Hospice-Palliative Medicine as a Model of Value-Based Healthcare.. <i>Journal of Korean Medical Science</i> , 2022 , 37, e111	4.7	1
19	Survival of all cancer patients in Korea through 2-year follow-up. <i>Journal of Korean Medical Science</i> , 2002 , 17, 448-52	4.7	0
18	Do Korean Medical Schools Provide Adequate End-of-Life Care Education? A Nationwide Survey of the Republic of Korea End-of-Life Care Curricula. <i>The Korean Journal of Hospice and Palliative Care</i> , 2019 , 22, 207-218	0.5	0
17	Evidence-based Healthcare in Korea. <i>Journal of the Korean Medical Association</i> , 2009 , 52, 934	0.5	
16	M20-03: Decision-making of lung cancer patients and family. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S211-S212		
15	Overexpression of Surface-Bound TGF- β 1 in Head & Neck Cancer Cell Lines Via Activated Immune Effector Cells-Derived Factors. <i>Journal of Immunotherapy</i> , 2005 , 28, 619	5	
14	Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data. <i>Annals of Translational Medicine</i> , 2020 , 8, 1389	3.2	

- 13 A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus. *The Korean Journal of Hematology*, **2005**, 40, 192
- 12 Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. *Korean Journal of Internal Medicine*, **2019**, 34, 894-901 2.5
- 11 Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution.. *Journal of Clinical Oncology*, **2014**, 32, 9543-9543 2.2
- 10 Effect of induction chemotherapy (IC) on survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with chemoradiotherapy: Single center experience.. *Journal of Clinical Oncology*, **2014**, 32, e17032-e17032 2.2
- 9 Poor prognostic factors in human papilloma virus-positive head and neck cancer: Who should not be candidate of de-escalated treatment?. *Journal of Clinical Oncology*, **2016**, 34, 6078-6078 2.2
- 8 Korean Cancer Patients' Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. *Journal of Clinical Oncology*, **2016**, 34, 10067-10067 2.2
- 7 Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience. *Blood*, **2016**, 128, 4222-4222 2.2
- 6 Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2012**, 30, 7566-7566 2.2
- 5 Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. *Journal of Clinical Oncology*, **2012**, 30, 5552-5552 2.2
- 4 A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.. *Journal of Clinical Oncology*, **2013**, 31, 8521-8521 2.2
- 3 Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.. *Journal of Clinical Oncology*, **2013**, 31, 2098-2098 2.2
- 2 The incidence, risk factors and prognostic implications of venous thromboembolism in Asian patients with non-small cell lung cancer.. *Journal of Clinical Oncology*, **2013**, 31, 1590-1590 2.2
- 1 Clinical significance of downstaging in patients treated with chemoradiotherapy for limited-disease small cell lung cancer.. *Journal of Clinical Oncology*, **2013**, 31, e18555-e18555 2.2